Inflammatory Biomarkers in Atrial Fibrillation

Author(s): Effimia Zacharia, Nikolaos Papageorgiou*, Adam Ioannou, Gerasimos Siasos, Spyridon Papaioannou, Manolis Vavuranakis, George Latsios, Charalampos Vlachopoulos, Konstantinos Toutouzas, Spyridon Deftereos, Rui Providência, Dimitris Tousoulis

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 5 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

During the last few years, a significant number of studies have attempted to clarify the underlying mechanisms that lead to the presentation of atrial fibrillation (AF). Inflammation is a key component of the pathophysiological processes that lead to the development of AF; the amplification of inflammatory pathways triggers AF, and, in tandem, AF increases the inflammatory state. Indeed, the plasma levels of several inflammatory biomarkers are elevated in patients with AF. In addition, the levels of specific inflammatory biomarkers may provide information regarding to the AF duration. Several small studies have assessed the role of anti-inflammatory treatment in atrial fibrillation but the results have been contradictory. Large-scale studies are needed to evaluate the role of inflammation in AF and whether anti-inflammatory medications should be routinely administered to patients with AF.

Keywords: Atrial fibrillation, inflammation, anti-inflammatory drugs, inflammatory biomarkers, C-reactive protein, interleukins, statins.

[1]
Fuster, V.; Rydén, L.E.; Asinger, R.W.; Cannom, D.S.; Crijns, H.J.; Frye, R.L.; Halperin, J.L.; Kay, G.N.; Klein, W.W.; Lévy, S.; McNamara, R.L.; Prystowsky, E.N.; Wann, L.S.; Wyse, D.G.; Gibbons, R.J.; Antman, E.M.; Alpert, J.S.; Faxon, D.P.; Fuster, V.; Gregoratos, G.; Hiratzka, L.F.; Jacobs, A.K.; Russell, R.O.; Smith, S.C., Jr; Klein, W.W.; Alonso-Garcia, A.; Blomström-Lundqvist, C.; de Backer, G.; Flather, M.; Hradec, J.; Oto, A.; Parkhomenko, A.; Silber, S.; Torbicki, A. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American college of cardiology/American heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the north American society of pacing and electrophysiology. Circulation, 2001, 104(17), 2118-2150.
[2]
Kannel, W.B.; Wolf, P.A.; Benjamin, E.J.; Levy, D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol., 1998, 82(8A), 2N-9N.
[3]
Grönefeld, G.C.; Lilienthal, J.; Kuck, K.H.; Hohnloser, S.H. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur. Heart J., 2003, 24(15), 1430-1436.
[4]
Steger, C.; Pratter, A.; Martinek-Bregel, M.; Avanzini, M.; Valentin, A.; Slany, J.; Stöllberger, C. Stroke patients with atrial fibrillation have a worse prognosis than patients without: Data from the Austrian Stroke registry. Eur. Heart J., 2004, 25(19), 1734-1740.
[5]
Watson, T.; Shantsila, E.; Lip, G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet, 2009, 373(9658), 155-166.
[6]
Toutouzas, K.; Synetos, A.; Drakopoulou, M.; Stefanadi, E.; Tousoulis, D.; Lerakis, S.; Stefanadis, C. The role of inflammation in atrial fibrillation: A myth or a fact? Am. J. Med. Sci., 2009, 338(6), 494-499.
[7]
Patel, P.; Dokainish, H.; Tsai, P.; Lakkis, N. Update on the association of inflammation and atrial fibrillation. J. Cardiovasc. Electrophysiol., 2010, 21(9), 1064-1070.
[8]
Friedrichs, K.; Klinke, A.; Baldus, S. Inflammatory pathways underlying atrial fibrillation. Trends Mol. Med., 2011, 17(10), 556-563.
[9]
Devaraj, S.; Singh, U.; Jialal, I. The evolving role of C-reactive protein in atherothrombosis. Clin. Chem., 2009, 55(2), 229-238.
[10]
Issac, T.T.; Dokainish, H.; Lakkis, N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J. Am. Coll. Cardiol., 2007, 50(21), 2021-2028.
[11]
Boldt, A.; Wetzel, U.; Lauschke, J.; Weigl, J.; Gummert, J.; Hindricks, G.; Kottkamp, H.; Dhein, S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart, 2004, 90(4), 400-405.
[12]
Kostin, S.; Klein, G.; Szalay, Z.; Hein, S.; Bauer, E.P.; Schaper, J. Structural correlate of atrial fibrillation in human patients. Cardiovasc. Res., 2002, 54(2), 361-379.
[13]
Hertervig, E.J.; Yuan, S.; Carlson, J.; Kongstad-Rasmussen, O.; Olsson, S.B. Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique. Clin. Physiol. Funct. Imaging, 2002, 22(1), 8-12.
[14]
Lau, C.P.; Tse, H.F. Electrical remodelling of chronic atrial fibrillation. Clin. Exp. Pharmacol. Physiol., 1997, 24(12), 982-983.
[15]
Van Wagoner, D.R. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J. Cardiovasc. Pharmacol., 2008, 52(4), 306-313.
[16]
Spodick, D.H. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA, 1976, 235(1), 39-41.
[17]
Morgera, T.; Di Lenarda, A.; Dreas, L.; Pinamonti, B.; Humar, F.; Bussani, R.; Silvestri, F.; Chersevani, D.; Camerini, F. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am. Heart J., 1992, 124(2), 455-467.
[18]
Bruins, P.; te Velthuis, H.; Yazdanbakhsh, A.P.; Jansen, P.G.; van Hardevelt, F.W.; de Beaumont, E.M.; Wildevuur, C.R.; Eijsman, L.; Trouwborst, A.; Hack, C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation, 1997, 96(10), 3542-3548.
[19]
Hu, Y.F.; Chen, Y.J.; Lin, Y.J.; Chen, S.A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol., 2015, 12(4), 230-243.
[20]
Ishii, Y.; Schuessler, R.B.; Gaynor, S.L.; Yamada, K.; Fu, A.S.; Boineau, J.P.; Damiano, R.J., Jr Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation, 2005, 111(22), 2881-2888.
[21]
Maixent, J.M.; Paganelli, F.; Scaglione, J.; Lévy, S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J. Cardiovasc. Electrophysiol., 1998, 9(6), 612-617.
[22]
Mandal, K.; Jahangiri, M.; Mukhin, M.; Poloniecki, J.; Camm, A.J.; Xu, Q. Association of anti-heat shock protein 65 antibodies with development of postoperative atrial fibrillation. Circulation, 2004, 110(17), 2588-2590.
[23]
Verheule, S.; Wilson, E.; Everett, T.I.V.; Shanbhag, S.; Golden, C.; Olgin, J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation, 2003, 107(20), 2615-2622.
[24]
Kamiyama, N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: Rabbit experimental model. Jpn. Circ. J., 1998, 62(11), 837-843.
[25]
Nakamura, Y.; Nakamura, K.; Fukushima-Kusano, K.; Ohta, K.; Matsubara, H.; Hamuro, T.; Yutani, C.; Ohe, T. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: Possible involvement in intracardiac thrombogenesis. Thromb. Res., 2003, 111(3), 137-142.
[26]
Mihm, M.J.; Yu, F.; Carnes, C.A.; Reiser, P.J.; McCarthy, P.M.; Van Wagoner, D.R.; Bauer, J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation, 2001, 104(2), 174-180.
[27]
Frustaci, A.; Chimenti, C.; Bellocci, F.; Morgante, E.; Russo, M.A.; Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96(4), 1180-1184.
[28]
Friedrichs, K.; Adam, M.; Remane, L.; Mollenhauer, M.; Rudolph, V.; Rudolph, T.K.; Andrié, R.P.; Stöckigt, F.; Schrickel, J.W.; Ravekes, T.; Deuschl, F.; Nickenig, G.; Willems, S.; Baldus, S.; Klinke, A. Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins. PLoS One, 2014, 9(2), e89307.
[29]
Yamashita, T.; Sekiguchi, A.; Iwasaki, Y.K.; Date, T.; Sagara, K.; Tanabe, H.; Suma, H.; Sawada, H.; Aizawa, T. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ. J., 2010, 74(2), 262-270.
[30]
Blake, G.J.; Ridker, P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol., 2003, 41(4)(Suppl. S), 37S-42S.
[31]
Fichtlscherer, S.; Zeiher, A.M. Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann. Med., 2000, 32(8), 515-518.
[32]
Chung, M.K.; Martin, D.O.; Sprecher, D.; Wazni, O.; Kanderian, A.; Carnes, C.A.; Bauer, J.A.; Tchou, P.J.; Niebauer, M.J.; Natale, A.; Van Wagoner, D.R. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104(24), 2886-2891.
[33]
Aviles, R.J.; Martin, D.O.; Apperson-Hansen, C.; Houghtaling, P.L.; Rautaharju, P.; Kronmal, R.A.; Tracy, R.P.; Van Wagoner, D.R.; Psaty, B.M.; Lauer, M.S.; Chung, M.K. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108(24), 3006-3010.
[34]
Asselbergs, F.W.; van den Berg, M.P.; Diercks, G.F.; van Gilst, W.H.; van Veldhuisen, D.J. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int. J. Cardiol., 2005, 98(1), 73-77.
[35]
Marott, S.C.; Nordestgaard, B.G.; Zacho, J.; Friberg, J.; Jensen, G.B.; Tybjaerg-Hansen, A.; Benn, M. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J. Am. Coll. Cardiol., 2010, 56(10), 789-795.
[36]
Watanabe, T.; Takeishi, Y.; Hirono, O.; Itoh, M.; Matsui, M.; Nakamura, K.; Tamada, Y.; Kubota, I. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels, 2005, 20(2), 45-49.
[37]
Pellegrino, P.L.; Brunetti, N.D.; De Gennaro, L.; Ziccardi, L.; Grimaldi, M.; Biase, M.D. Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset. Intern. Emerg. Med., 2013, 8(2), 123-128.
[38]
Marcus, G.M.; Smith, L.M.; Ordovas, K.; Scheinman, M.M.; Kim, A.M.; Badhwar, N.; Lee, R.J.; Tseng, Z.H.; Lee, B.K.; Olgin, J.E. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm, 2010, 7(2), 149-154.
[39]
Warner, S.J.; Libby, P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J. Immunol., 1989, 142(1), 100-109.
[40]
Qu, Y.C.; Du, Y.M.; Wu, S.L.; Chen, Q.X.; Wu, H.L.; Zhou, S.F. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand. Cardiovasc. J., 2009, 43(5), 292-297.
[41]
Deng, H.; Xue, Y.M.; Zhan, X.Z.; Liao, H.T.; Guo, H.M.; Wu, S.L. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. Chin. Med. J. (Engl.), 2011, 124(13), 1976-1982.
[42]
Li, J.; Solus, J.; Chen, Q.; Rho, Y.H.; Milne, G.; Stein, C.M.; Darbar, D. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm, 2010, 7(4), 438-444.
[43]
Olejniczak, K.; Kasprzak, A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. Med. Sci. Monit., 2008, 14(10), RA179-RA189.
[44]
Kourliouros, A.; Savelieva, I.; Kiotsekoglou, A.; Jahangiri, M.; Camm, J. Current concepts in the pathogenesis of atrial fibrillation. Am. Heart J., 2009, 157(2), 243-252.
[45]
Melenovsky, V.; Lip, G.Y. Interleukin-8 and atrial fibrillation. Europace, 2008, 10(7), 784-785.
[46]
Hak, L.; Mysliwska, J.; Wieckiewicz, J.; Szyndler, K.; Siebert, J.; Rogowski, J. Interleukin-2 as a predictor of early postoperative atrial fibril-lation after cardiopulmonary bypass graft (CABG). J. Interferon Cytokine Res., 2009, 29(6), 327-332.
[47]
Marcus, G.M.; Whooley, M.A.; Glidden, D.V.; Pawlikowska, L.; Zaroff, J.G.; Olgin, J.E. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the heart and soul study. Am. Heart J., 2008, 155(2), 303-309.
[48]
Kaireviciute, D.; Blann, A.D.; Balakrishnan, B.; Lane, D.A.; Patel, J.V.; Uzdavinys, G.; Norkunas, G.; Kalinauskas, G.; Sirvydis, V.; Aidietis, A.; Lip, G.Y. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb. Haemost., 2010, 104(1), 122-127.
[49]
Gedikli, O.; Dogan, A.; Altuntas, I.; Altinbas, A.; Ozaydin, M.; Akturk, O.; Acar, G. Inflammatory markers according to types of atrial fibrillation. Int. J. Cardiol., 2007, 120(2), 193-197.
[50]
Liuba, I.; Ahlmroth, H.; Jonasson, L.; Englund, A.; Jönsson, A.; Säfström, K.; Walfridsson, H. Source of inflammatory markers in patients with atrial fibrillation. Europace, 2008, 10(7), 848-853.
[51]
De Gennaro, L.; Brunetti, N.D.; Montrone, D.; De Rosa, F.; Cuculo, A.; Di Biase, M. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur. J. Clin. Invest., 2012, 42(4), 371-375.
[52]
Santulli, G.; Iaccarino, G.; De Luca, N.; Trimarco, B.; Condorelli, G. Atrial fibrillation and microRNAs. Front. Physiol., 2014, 5, 15.
[53]
Lu, Y.; Zhang, Y.; Wang, N.; Pan, Z.; Gao, X.; Zhang, F.; Zhang, Y.; Shan, H.; Luo, X.; Bai, Y.; Sun, L.; Song, W.; Xu, C.; Wang, Z.; Yang, B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation, 2010, 122(23), 2378-2387.
[54]
Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; Castoldi, M.; Soutschek, J.; Koteliansky, V.; Rosenwald, A.; Basson, M.A.; Licht, J.D.; Pena, J.T.; Rouhanifard, S.H.; Muckenthaler, M.U.; Tuschl, T.; Martin, G.R.; Bauersachs, J.; Engelhardt, S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456(7224), 980-984.
[55]
Ando, Y.; Yang, G.X.; Kenny, T.P.; Kawata, K.; Zhang, W.; Huang, W.; Leung, P.S.; Lian, Z.X.; Okazaki, K.; Ansari, A.A.; He, X.S.; Invernizzi, P.; Ridgway, W.M.; Lu, Q.; Gershwin, M.E. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J. Autoimmun., 2013, 41, 111-119.
[56]
Adam, O.; Löhfelm, B.; Thum, T.; Gupta, S.K.; Puhl, S.L.; Schäfers, H.J.; Böhm, M.; Laufs, U. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res. Cardiol., 2012, 107(5), 278.
[57]
Zhang, H.; Liu, L.; Hu, J.; Song, L. MicroRNA regulatory network revealing the mechanism of inflammation in atrial fibrillation. Med. Sci. Monit., 2015, 21, 3505-3513.
[58]
Wang, J.; Song, S.; Xie, C.; Han, J.; Li, Y.; Shi, J.; Xin, M.; Wang, J.; Luo, T.; Meng, X.; Yang, B. MicroRNA profiling in the left atrium in patients with non-valvular paroxysmal atrial fibrillation. BMC Cardiovasc. Disord., 2015, 15, 97.
[59]
Harling, L.; Lambert, J.; Ashrafian, H.; Darzi, A.; Gooderham, N.J.; Athanasiou, T. Elevated serum microRNA 483-5p levels may predict pa-tients at risk of post-operative atrial fibrillation. Eur. J. Cardiothorac. Surg., 2017, 51(1), 73-78.
[60]
Rienstra, M.; Yin, X.; Larson, M.G.; Fontes, J.D.; Magnani, J.W.; McManus, D.D.; McCabe, E.L.; Coglianese, E.E.; Amponsah, M.; Ho, J.E.; Januzzi, J.L., Jr; Wollert, K.C.; Fradley, M.G.; Vasan, R.S.; Ellinor, P.T.; Wang, T.J.; Benjamin, E.J. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am. Heart J., 2014, 167(1), 109-115.e2.
[61]
Abdelhadi, R.H.; Gurm, H.S.; Van Wagoner, D.R.; Chung, M.K. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am. J. Cardiol., 2004, 93(9), 1176-1178.
[62]
Misialek, J.R.; Bekwelem, W.; Chen, L.Y.; Loehr, L.R.; Agarwal, S.K.; Soliman, E.Z.; Norby, F.L.; Alonso, A. Association of White Blood Cell Count and Differential with the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One, 2015, 10(8), e0136219.
[63]
Stellos, K.; Rahmann, A.; Kilias, A.; Ruf, M.; Sopova, K.; Stamatelopoulos, K.; Jorbenadze, R.; Weretka, S.; Geisler, T.; Gawaz, M.; Weig, H.J.; Bigalke, B. Expression of platelet-bound stromal cell-derived factor-1 in patients with non-valvular atrial fibrillation and ischemic heart disease. J. Thromb. Haemost., 2012, 10(1), 49-55.
[64]
Henningsen, K.M.; Nilsson, B.; Bruunsgaard, H.; Chen, X.; Pedersen, B.K.; Svendsen, J.H. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand. Cardiovasc. J., 2009, 43(5), 285-291.
[65]
Henningsen, K.M.; Therkelsen, S.K.; Bruunsgaard, H.; Krabbe, K.S.; Pedersen, B.K.; Svendsen, J.H. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand. J. Clin. Lab. Invest., 2009, 69(3), 425-432.
[66]
Leftheriotis, D.I.; Fountoulaki, K.T.; Flevari, P.G.; Parissis, J.T.; Panou, F.K.; Andreadou, I.T.; Venetsanou, K.S.; Iliodromitis, E.K.; Kremastinos, D.T. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int. J. Cardiol., 2009, 135(3), 361-369.
[67]
Kimura, T.; Takatsuki, S.; Inagawa, K.; Katsumata, Y.; Nishiyama, T.; Nishiyama, N.; Fukumoto, K.; Aizawa, Y.; Tanimoto, Y.; Tanimoto, K.; Fukuda, K. Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. Heart Lung Circ., 2014, 23(7), 636-643.
[68]
Kornej, J.; Reinhardt, C.; Kosiuk, J.; Arya, A.; Hindricks, G.; Adams, V.; Husser, D.; Bollmann, A. Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation. J. Transl. Med., 2013, 11, 49.
[69]
Ederhy, S.; Di Angelantonio, E.; Dufaitre, G.; Meuleman, C.; Masliah, J.; Boyer-Chatenet, L.; Boccara, F.; Cohen, A. C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. Int. J. Cardiol., 2012, 159(1), 40-46.
[70]
Aulin, J.; Siegbahn, A.; Hijazi, Z.; Ezekowitz, M.D.; Andersson, U.; Connolly, S.J.; Huber, K.; Reilly, P.A.; Wallentin, L.; Oldgren, J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am. Heart J., 2015, 170(6), 1151-1160.
[71]
Pinto, A.; Tuttolomondo, A.; Casuccio, A.; Di Raimondo, D.; Di Sciacca, R.; Arnao, V.; Licata, G. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci., 2009, 116(10), 781-789.
[72]
Conway, D.S.; Buggins, P.; Hughes, E.; Lip, G.Y. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J., 2004, 148(3), 462-466.
[73]
Wallentin, L.; Hijazi, Z.; Andersson, U.; Alexander, J.H.; De Caterina, R.; Hanna, M.; Horowitz, J.D.; Hylek, E.M.; Lopes, R.D.; Asberg, S.; Granger, C.B.; Siegbahn, A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation, 2014, 130(21), 1847-1858.
[74]
Marín, F.; Corral, J.; Roldán, V.; González-Conejero, R.; del Rey, M.L.; Sogorb, F.; Lip, G.Y.; Vicente, V. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J. Mol. Cell. Cardiol., 2004, 37(3), 699-704.
[75]
Roldán, V.; Arroyo, A.B.; Salloum-Asfar, S.; Manzano-Fernández, S.; García-Barberá, N.; Marín, F.; Vicente, V.; González-Conejero, R.; Martínez, C. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb. Haemost., 2014, 112(4), 781-788.
[76]
Tamarat, R.; Silvestre, J.S.; Durie, M.; Levy, B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab. Invest., 2002, 82(6), 747-756.
[77]
Ruiz-Ortega, M.; Ruperez, M.; Lorenzo, O.; Esteban, V.; Blanco, J.; Mezzano, S.; Egido, J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. Suppl., 2002, (82), S12-S22.
[78]
Suzuki, Y.; Ruiz-Ortega, M.; Lorenzo, O.; Ruperez, M.; Esteban, V.; Egido, J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol., 2003, 35(6), 881-900.
[79]
Tham, D.M.; Martin-McNulty, B.; Wang, Y.X.; Wilson, D.W.; Vergona, R.; Sullivan, M.E.; Dole, W.; Rutledge, J.C. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics, 2002, 11(1), 21-30.
[80]
Maksimowicz-McKinnon, K.; Bhatt, D.L.; Calabrese, L.H. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr. Opin. Rheumatol., 2004, 16(1), 18-24.
[81]
Peng, J.; Gurantz, D.; Tran, V.; Cowling, R.T.; Greenberg, B.H. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ. Res., 2002, 91(12), 1119-1126.
[82]
Wang, Y.; Li, Y.; Wu, Y.; Jia, L.; Wang, J.; Xie, B.; Hui, M.; Du, J. 5TNF-α and IL-1β neutralization ameliorates angiotensin II-induced cardiac damage in male mice. Endocrinology, 2014, 155(7), 2677-2687.
[83]
Freestone, B.; Beevers, D.G.; Lip, G.Y. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? J. Hum. Hypertens., 2004, 18(7), 461-465.
[84]
Cardin, S.; Li, D.; Thorin-Trescases, N.; Leung, T.K.; Thorin, E.; Nattel, S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc. Res., 2003, 60(2), 315-325.
[85]
Yongjun, Q.; Huanzhang, S.; Wenxia, Z.; Hong, T.; Xijun, X. From changes in local RAAS to structural remodeling of the left atrium: A beautiful cycle in atrial fibrillation. Herz, 2015, 40(3), 514-520.
[86]
Tsai, C.T.; Lai, L.P.; Lin, J.L.; Chiang, F.T.; Hwang, J.J.; Ritchie, M.D.; Moore, J.H.; Hsu, K.L.; Tseng, C.D.; Liau, C.S.; Tseng, Y.Z. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation, 2004, 109(13), 1640-1646.
[87]
Sovari, A.A.; Dudley, S.C., Jr Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. Front. Physiol., 2012, 3, 311.
[88]
Negi, S.; Sovari, A.A.; Dudley, S.C., Jr Atrial fibrillation: the emerging role of inflammation and oxidative stress. Cardiovasc. Hematol. Disord. Drug Targets, 2010, 10(4), 262-268.
[89]
Neuman, R.B.; Bloom, H.L.; Shukrullah, I.; Darrow, L.A.; Kleinbaum, D.; Jones, D.P.; Dudley, S.C., Jr Oxidative stress markers are associated with persistent atrial fibrillation. Clin. Chem., 2007, 53(9), 1652-1657.
[90]
Kim, Y.H.; Lim, D.S.; Lee, J.H.; Shim, W.J.; Ro, Y.M.; Park, G.H.; Becker, K.G.; Cho-Chung, Y.S.; Kim, M.K. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp. Mol. Med., 2003, 35(5), 336-349.
[91]
Marrouche, N.F.; Wilber, D.; Hindricks, G.; Jais, P.; Akoum, N.; Marchlinski, F.; Kholmovski, E.; Burgon, N.; Hu, N.; Mont, L.; Deneke, T.; Duytschaever, M.; Neumann, T.; Mansour, M.; Mahnkopf, C.; Herweg, B.; Daoud, E.; Wissner, E.; Bansmann, P.; Brachmann, J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA, 2014, 311(5), 498-506.
[92]
Canpolat, U.; Aytemir, K.; Hazirolan, T.; Özer, N.; Oto, A. Serum YKL-40 as a marker of left atrial fibrosis assessed by delayed enhancement MRI in lone atrial fibrillation. Pacing Clin. Electrophysiol., 2015, 38(12), 1386-1395.
[93]
Sazonova, S.I.; Ilyushenkova, J.N.; Lishmanov, Y.B.; Batalov, R.E.; Sazonov, A.E.; Larionova, L.A.; Nesterov, E.A.; Varlamova, N.V.; Rogovskaya, J.V.; Shelkovnikova, T.A.; Popov, S.V. Assessment of radiological techniques application possibility for non-invasive diagnostics of latent inflammatory processes in myocardium in patients with atrial fibrillation. Ann. Nucl. Med., 2016, 30(10), 738-748.
[94]
Toutouzas, K.; Drakopoulou, M.; Dilaveris, P.; Vaina, S.; Gatzoulis, K.; Karabelas, J.; Riga, M.; Stefanadi, E.; Synetos, A.; Vlasis, K.; Stefanadis, C. Inflammation in lone atrial fibrillation: New insights by coronary sinus thermography. Int. J. Cardiol., 2009, 134(3), 345-350.
[95]
Mazurek, T.; Kiliszek, M.; Kobylecka, M.; Skubisz-Głuchowska, J.; Kochman, J.; Filipiak, K.; Królicki, L.; Opolski, G. Relation of proinflammatory activity of epicardial adipose tissue to the occurrence of atrial fibrillation. Am. J. Cardiol., 2014, 113(9), 1505-1508.
[96]
Patti, G.; Chello, M.; Candura, D.; Pasceri, V.; D’Ambrosio, A.; Covino, E.; Di Sciascio, G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation, 2006, 114(14), 1455-1461.
[97]
Kourliouros, A.; De Souza, A.; Roberts, N.; Marciniak, A.; Tsiouris, A.; Valencia, O.; Camm, J.; Jahangiri, M. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann. Thorac. Surg., 2008, 85(5), 1515-1520.
[98]
Dehghani, M.R.; Kasianzadeh, M.; Rezaei, Y.; Sepehrvand, N. Atorvastatin reduces the incidence of postoperative atrial fibrillation in statin-naive patients undergoing isolated heart valve surgery: A double-blind, placebo-controlled randomized trial. J. Cardiovasc. Pharmacol. Ther., 2015, 20(5), 465-472.
[99]
García-Fernández, A.; Marín, F.; Mainar, L.; Roldán, V.; Martínez, J.G. Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol., 2006, 98(9), 1299-1300.
[100]
Virani, S.S.; Nambi, V.; Razavi, M.; Lee, V.V.; Elayda, M.; Wilson, J.M.; Ballantyne, C.M. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am. Heart J., 2008, 155(3), 541-546.
[101]
Calò, L.; Bianconi, L.; Colivicchi, F.; Lamberti, F.; Loricchio, M.L.; de Ruvo, E.; Meo, A.; Pandozi, C.; Staibano, M.; Santini, M. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A randomized, controlled trial. J. Am. Coll. Cardiol., 2005, 45(10), 1723-1728.
[102]
Saravanan, P.; Bridgewater, B.; West, A.L.; O’Neill, S.C.; Calder, P.C.; Davidson, N.C. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol, 2010, 3(1), 46-53.
[103]
Darghosian, L.; Free, M.; Li, J.; Gebretsadik, T.; Bian, A.; Shintani, A.; McBride, B.F.; Solus, J.; Milne, G.; Crossley, G.H.; Thompson, D.; Vidaillet, H.; Okafor, H.; Darbar, D.; Murray, K.T.; Stein, C.M. Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation. Am. J. Cardiol., 2015, 115(2), 196-201.
[104]
Nigam, A.; Talajic, M.; Roy, D.; Nattel, S.; Lambert, J.; Nozza, A.; Jones, P.; Ramprasath, V.R.; O’Hara, G.; Kopecky, S.; Brophy, J.M.; Tardif, J.C. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. J. Am. Coll. Cardiol., 2014, 64(14), 1441-1448.
[105]
Martínez-González, M.A.; Toledo, E.; Arós, F.; Fiol, M.; Corella, D.; Salas-Salvadó, J.; Ros, E.; Covas, M.I.; Fernández-Crehuet, J.; Lapetra, J.; Muñoz, M.A.; Fitó, M.; Serra-Majem, L.; Pintó, X.; Lamuela-Raventós, R.M.; Sorlí, J.V.; Babio, N.; Buil-Cosiales, P.; Ruiz-Gutierrez, V.; Estruch, R.; Alonso, A. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevención con Dieta Mediterránea) trial. Circulation, 2014, 130(1), 18-26.
[106]
Dernellis, J.; Panaretou, M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J., 2004, 25(13), 1100-1107.
[107]
Halonen, J.; Halonen, P.; Järvinen, O.; Taskinen, P.; Auvinen, T.; Tarkka, M.; Hippeläinen, M.; Juvonen, T.; Hartikainen, J.; Hakala, T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA, 2007, 297(14), 1562-1567.
[108]
Vermes, E.; Tardif, J.C.; Bourassa, M.G.; Racine, N.; Levesque, S.; White, M.; Guerra, P.G.; Ducharme, A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation, 2003, 107(23), 2926-2931.
[109]
Miceli, A.; Capoun, R.; Fino, C.; Narayan, P.; Bryan, A.J.; Angelini, G.D.; Caputo, M. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol., 2009, 54(19), 1778-1784.
[110]
Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: A randomized controlled study. J. Am. Coll. Cardiol., 2012, 60(18), 1790-1796.
[111]
Imazio, M.; Brucato, A.; Ferrazzi, P.; Rovere, M.E.; Gandino, A.; Cemin, R.; Ferrua, S.; Belli, R.; Maestroni, S.; Simon, C.; Zingarelli, E.; Barosi, A.; Sansone, F.; Patrini, D.; Vitali, E.; Trinchero, R.; Spodick, D.H.; Adler, Y. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation, 2011, 124(21), 2290-2295.
[112]
Zhao, Q.; Kebbati, A.H.; Zhang, Y.; Tang, Y.; Okello, E.; Huang, C. Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. J. Investig. Med., 2015, 63(5), 735-739.
[113]
Zemer-Wassercug, N.; Haim, M.; Leshem-Lev, D.; Orvin, K.L.; Vaduganathan, M.; Gutstein, A.; Kadmon, E.; Mager, A.; Kornowski, R.; Lev, E.I. The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J. Thromb. Thrombolysis, 2015, 40(3), 340-346.
[114]
Shimizu, A.; Nozaki, A.; Rudy, Y.; Waldo, A.L. Onset of induced atrial flutter in the canine pericarditis model. J. Am. Coll. Cardiol., 1991, 17(5), 1223-1234.
[115]
Conen, D.; Ridker, P.M.; Everett, B.M.; Tedrow, U.B.; Rose, L.; Cook, N.R.; Buring, J.E.; Albert, C.M. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur. Heart J., 2010, 31(14), 1730-1736.
[116]
Marcus, G.M.; Smith, L.M.; Glidden, D.V.; Wilson, E.; McCabe, J.M.; Whiteman, D.; Tseng, Z.H.; Badhwar, N.; Lee, B.K.; Lee, R.J.; Scheinman, M.M.; Olgin, J.E. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm, 2008, 5(2), 215-221.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 5
Year: 2019
Page: [837 - 854]
Pages: 18
DOI: 10.2174/0929867324666170727103357
Price: $65

Article Metrics

PDF: 60
HTML: 13
EPUB: 1